5933-28-8

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
5-Benzyloxyindole-3-acetamide is used as a chemical intermediate for the synthesis of new bioactive molecules and pharmaceutical agents. Its unique chemical structure and properties make it a promising candidate for the development of new drugs for various medicinal purposes.
Used in Medicinal Chemistry:
5-Benzyloxyindole-3-acetamide is used as a compound of interest in the field of medicinal chemistry. Its benzyloxy group may confer specific biological activities or pharmacological properties that could be exploited in the development of novel therapeutics.
Used in Pharmaceutical Science:
5-Benzyloxyindole-3-acetamide is used in pharmaceutical science for further investigation and development of new drugs for various medicinal purposes. Its potential applications make it a valuable compound for research and development in this field.

InChI:InChI=1/C17H16N2O2/c18-17(20)8-13-10-19-16-7-6-14(9-15(13)16)21-11-12-4-2-1-3-5-12/h1-7,9-10,19H,8,11H2,(H2,18,20)

Upstream product

• 92438-11-4 5-Benzyloxy-2,ω-dinitro-styrol 
• 1453-97-0 5-benzyloxygramine 
• 65881-15-4 (1-acetyl-5-benzyloxy-indol-3-yl)-acetonitrile 
• 1215-59-4 5-benzyloxy-1H-indole 

Downstream Products

• 52055-23-9 5-benzyloxytryptamine hydrochloride 
• 50-67-9 3-(2-aminoethyl)-1H-indol-5-ol 
• 20776-45-8 5-benzyloxytryptamine 
• 5933-27-7 5-hydroxyindole-3-acetamide 

Relevant academic research and scientific papers

Brain-specific drug delivery

The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine pyridinium salt redox carrier, with the proviso that when [DHC] is STR1 wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH2 or OH function group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entitles [D--QC]+ X- are also disclosed.

Brain-specific drug delivery

The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine pyridinium salt redox carrier, with the proviso that when [DHC] is STR1 wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D-QC]+ Y- are also disclosed.